SMARCA2 and esophageal squamous cell carcinoma: In contrast, SMARCA4 loss inhibits the growth of acute myeloid leukemia cells [67], melanoma [68,69], and SMARCA2-deficient esophageal squamous cell carcinoma (ESCC) [70].